Comparing BioLargo (BLGO) and Its Competitors

BioLargo (NASDAQ:BLGO) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its competitors? We will compare BioLargo to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings.

Institutional and Insider Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares BioLargo and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.17
BioLargo Competitors	$6.84 billion	$211.64 million	65.96

BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

BioLargo has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.81, suggesting that their average share price is 81% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BioLargo and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1249	1568	44	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 15.62%. Given BioLargo’s competitors higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its competitors.

Profitability

This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-591.84%	5.15%	-0.65%

Summary

BioLargo competitors beat BioLargo on 8 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.